

## IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
<b>IMPAACT 2043/A5425</b>	A Randomized Study of Long-Acting ART in Postpartum Women at Risk for Adherence Challenges (PRACTICAL)	US/INTL	In Development	Therapeutics	10-Nov-24	09-Nov-25	17-Dec-25	06-Jan-27	31-Dec-28	TBD	NA
<b>IMPAACT 2042</b>	Phase I/II Trial to Evaluate the Impact of Three Broadly Neutralizing Antibodies or Analytic Treatment Interruption on Viral Reservoir, Immune Function, and Maintenance of HIV Suppression in Early-Treated Children in Botswana	INTL	In Development	Cure & Immunotherapy	10-Nov-24	09-May-26	07-Aug-26	12-Mar-28	12-Feb-29	TBD	NA
<b>IMPAACT 2020</b>	A Phase II Study of Shortened Oral Novel Treatment for Rifampicin-Resistant Tuberculosis in Children	INTL	In Development	Tuberculosis	10-Nov-24	26-May-25	09-Jan-26	09-Apr-28	23-Apr-28	112 children and their caregivers	NA
<b>IMPAACT 2038</b>	Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age	US	In Development	Cure & Immunotherapy	31-Mar-24	19-May-24	23-Jun-24	23-Jun-26	22-Oct-26	70	NA
<b>IMPAACT 2041</b>	Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated During Pregnancy in People with Hepatitis C with or without HIV	US	In Development	Therapeutics	31-Mar-24	29-Jun-24	29-Jul-24	29-Jul-25	26-Mar-26	30 pairs	NA
<b>IMPAACT 2039</b>	Phase I/II Study of the Safety, Immunogenicity, Efficacy of HIVconsVX Vaccines in Children Living with HIV	US/INTL	In Development	Cure & Immunotherapy	31-Jul-24	29-Oct-24	27-Jan-25	TBD	TBD	42 (Part A); 90 (Part B)	NA
<b>IMPAACT 2040</b>	Phase I/II Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed People with HIV During Pregnancy and Postpartum	US/INTL	In Development	Therapeutics	15-Dec-23	12-Jun-24	10-Jul-24	03-Oct-25	28-Sep-26	45 pairs	NA
<b>IMPAACT 2037</b>	Phase I Open Label Study of the Safety and Pharmacokinetics of PGT121.414.LS Alone and in Combination with VRC07-523LS in Infants Exposed to HIV-1	US/INTL	In Development	Therapeutics	31-Jan-24	29-Jul-24	28-Aug-24	26-Feb-26	26-Feb-28	48	NA
<b>IMPAACT 2024</b>	Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to less than 13 Years of Age with and without HIV	INTL	In Development	Tuberculosis	30-Jan-24	30-Jun-24	31-Aug-24	31-Aug-26	28-Feb-27	80	NA
<b>IMPAACT 2036</b>	Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV Two to Less than 12 Years of Age	US/INTL	Pending	Therapeutics	04-Oct-22	31-Dec-23	01-Mar-24	02-Sep-25	02-Sep-26	90	NA
<b>IMPAACT 2035/HVTN 604</b>	Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa	INTL	Pending	Tuberculosis	13-Jul-22	29-Feb-24	30-Apr-24	30-Oct-25	30-Oct-26	480	NA
<b>IMPAACT 2016</b>	Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings	INTL	Enrolling	Brain & Mental Health	08-Nov-18	27-Nov-19	11-Nov-23	30-Nov-24	30-Nov-25	256	24 youth, 23 caregivers (pilot test)

TBD = information is to be added once timeline is clearer  
 Grey text boxes indicates a projected (rather than actual) date

Based on data available through 14 November 2023  
 Page 1 of 3

## IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
<b>IMPAACT 2034</b>	Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis	INTL	Enrolling	Tuberculosis	04-Aug-22	17-Feb-23	03-Oct-23	01-Jan-26	15-Jan-26	72	6
<b>IMPAACT 2023</b>	A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1	US/INTL	Enrolling	Therapeutics	25-Oct-21	26-Sep-22	05-Oct-22	30-May-25	30-Sep-25	108	12
<b>IMPAACT 2028</b>	Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV Infection	US/INTL	Enrolling	Cure & Immunotherapy	31-Dec-20	08-Nov-21	02-Feb-22	30-Nov-26	30-Nov-27	250	86
<b>IMPAACT 2026</b>	Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum	US/INTL	Enrolling	Therapeutics	04-Feb-20	08-Jun-21	01-Sep-21	30-Apr-26	01-Sep-26	325	83 pairs
<b>IMPAACT 2021</b>	Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/11314L, RSV 6120/ΔNS2/1030s, or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age	US	Enrolling	Cure & Immunotherapy	28-Mar-19	16-May-19	20-Jun-19	01-Dec-23	31-Mar-24	130	66
<b>IMPAACT 2003b/A5300b</b>	Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients (PHOENIX MDR-TB)	INTL	Enrolling	Tuberculosis	2-Oct-18 (V2)	03-Jun-19	13-Jun-19	31-Jul-24	02-Nov-26	3452 (household); 1726 (index)	2,626 (household); 1,395 (index)
<b>IMPAACT 2005</b>	A Phase I/II Open-label, Single-Arm Study to Evaluate the PK, Safety, & Tolerability of Delamanid in Combination with OBR for MDR-TB in Children with MDR-TB with and without HIV	INTL	Enrolling	Tuberculosis	21-Mar-17	30-Jan-18	18-Feb-19	30-Nov-23	02-Oct-25	48	24
<b>P1115</b>	Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study	US/INTL	Enrolling	Cure & Immunotherapy	20-Mar-14	24-Jun-14	23-Jan-15	31-Dec-23	30-Dec-32	905 pairs	889 pairs
<b>P1108</b>	A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children, and Adolescents with RR-TB Disease, Living with or without HIV	INTL	Enrolling	Tuberculosis	09-Mar-16	18-Aug-17	21-Sep-17	25-Aug-23 (pending confirmation of evaluability)	31-Aug-25	72	54
<b>IMPAACT 2017</b>	Phase I/II Study of Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents: MOCHA (More Options for Children and Adolescents)	US/INTL	Closed to Accrual	Therapeutics	16-Mar-18	19-Mar-19	03-Apr-19	27-Oct-23	31-Aug-25	155	155
<b>IMPAACT 2009</b>	Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants	INTL	Closed to Accrual	Therapeutics	02-Nov-17	09-Jul-18	04-Mar-19	15-Dec-22	15-Feb-24	390	390 pairs

TBD = information is to be added once timeline is clearer  
 Grey text boxes indicates a projected (rather than actual) date

Based on data available through 14 November 2023  
 Page 2 of 3

# IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
P1093	Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents	US/INTL	POS/PAC*	Therapeutics	21-Dec-10	14-Mar-11	20-Apr-11	19-Feb-20	18-Oct-23	300	181
* last 8 months											
<p style="text-align: center;"> <b>Research Area: Brain &amp; Mental Health</b>      2016  <b>Cure &amp; Immunotherapy</b>      2042, 2039, 2038, 2028, 2021, P1115  <b>Therapeutics</b>      2043/A5425, 2041, 2040, 2037, 2036, 2026, 2023, 2017, 2009, P1093  <b>Tuberculosis</b>      2035/HVTN 604, 2034, 2024, 2020, 2005, 2003b/A5300b, P1108         </p>											

TBD = information is to be added once timeline is clearer  
 Grey text boxes indicates a projected (rather than actual) date